Tyrosine kinase receptors Press Release

Title Picture
06/02/2018 - 08:42
Drug Combination Slows Growth of Most Common Type of Advanced Breast Cancer
Memorial Sloan Kettering Cancer Center's picture
MSKCC
04/10/2018 - 04:40
Illumina and Loxo Oncology to Partner on Developing Next-Generation Sequencing-Based Pan-Cancer Companion Diagnostics
Illumina's picture
Illumina
04/04/2018 - 06:48
U.S. FDA and European Medicines Agency Accept Regulatory Submissions for Review of Dacomitinib to Treat Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mutations
Pfizer's picture
Pfizer
03/15/2018 - 05:46
ArQule to Present Data at the 2018 American Association for Cancer Research (AACR) Annual Meeting
ArQule's picture
ArQule
03/05/2018 - 23:13
Resistance to vandetanib through allosteric effects
Kyoto University's picture
KyotoUniversity
02/12/2018 - 08:23
U.S., EU and Japan Health Authorities Accept Regulatory Submissions for Review of Pfizers Third-Generation ALK Inhibitor Lorlatinib
Pfizer's picture
Pfizer
02/04/2018 - 00:52
Old drug may have new tricks for fighting cancer
Biodesign Institute's picture
Biodesign Institute
01/31/2018 - 20:59
Further Improving Access to Therapies for Non-Small Cell Lung Cancer
Chugai's picture
Chugai
12/22/2017 - 00:53
Roche and Ignyta reach definitive merger agreement
Rocheusa's picture
Rocheusa
12/20/2017 - 23:41
European Commission approves Roches Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer
Rocheusa's picture
Rocheusa
11/21/2017 - 05:11
ArQule Announces Dosing in a Registrational Trial of FGFR Inhibitor, Derazantinib, for Treatment of Intrahepatic Cholangiocarcinoma
ArQule's picture
ArQule
11/17/2017 - 08:52
Celldex Therapeutics Initiates Phase 2 Combination Study of CDX-3379 and Cetuximab in Head and Neck Squamous Cell Carcinoma
Celldex's picture
Celldex
11/11/2017 - 13:38
Former SfN President Moses V. Chao Receives Julius Axelrod Prize
Society for Neuroscience's picture
Society for Neu...
11/06/2017 - 22:30
FDA approves Roches Alecensa (alectinib) as first-line treatment for people with specific type of lung cancer
Rocheusa's picture
Rocheusa
10/30/2017 - 02:28
Spectrum Pharmaceuticals Announces Initiation of a Multicenter Phase 2 Trial of Poziotinib in Non-Small Cell Lung Cancer (NSCLC) Patients with Exon 20 Insertion Mutation in EGFR or HER2
Spectrum's picture
Spectrum
10/16/2017 - 23:29
Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in Japan
Spectrum's picture
Spectrum
10/16/2017 - 06:06
Pfizer Presents Full Results from Phase 2 Study of Next-Generation Investigational ALK-Inhibitor Lorlatinib in ALK-Positive and ROS1-Positive Advanced Non-Small Cell Lung Cancer
Pfizer's picture
Pfizer
10/13/2017 - 04:56
CHMP recommends EU approval of Roches Alecensa (alectinib) as a first-line treatment for people with ALK-positive NSCLC
Rocheusa's picture
Rocheusa
09/11/2017 - 07:56
Pfizer Presents Overall Survival Data of XALKORI in Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer
Pfizer's picture
Pfizer
09/06/2017 - 01:04
Roche presents data from global phase III study showing significant clinical benefit of Alecensa (alectinib) in later-line advanced ALK-positive lung cancer
Rocheusa's picture
Rocheusa
08/02/2017 - 00:42
FDA Grants Genentechs Alecensa Priority Review for Initial Treatment of People with ALK-Positive Lung Cancer
Genentech's picture
Genentech
06/06/2017 - 02:10
Data of Chugai's Alecensa Presented at the American Society of Clinical Oncology on Global Phase III ALEX Study
Chugai's picture
Chugai
06/05/2017 - 04:22
Phase III Study Showed Genentechs Alecensa (Alectinib) Reduced the Risk of Disease Progression or Death by More Than Half Versus Crizotinib as First-Line Treatment in a Specific Type of Lung Cancer
Genentech's picture
Genentech
06/05/2017 - 03:33
Phase III study showed Roches Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer
Rocheusa's picture
Rocheusa
06/03/2017 - 06:33
ArQule Presents Phase 1/2 Clinical Data with ARQ 087 in Intrahepatic Cholangiocarcinoma at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
ArQule's picture
ArQule
06/03/2017 - 05:22
Results Indicate That Larotrectinib Is Effective as the First Novel Targeted Therapy to Show a Consistent Response across Multiple Tumor Types in Adult and Pediatric Patients
Memorial Sloan Kettering Cancer Center's picture
MSKCC
05/17/2017 - 15:13
ArQule to Present Clinical Data at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
ArQule's picture
ArQule
05/11/2017 - 01:58
Results of the J-ALEX Study for Chugai's Alecensa are Published in The Lancet Online
Chugai's picture
Chugai
04/27/2017 - 04:19
Pfizers Next-Generation ALK/ROS1 Inhibitor, Lorlatinib, Granted Breakthrough Therapy Designation from FDA for ALK-Positive Metastatic Non-Small Cell Lung Cancer
Pfizer's picture
Pfizer
04/10/2017 - 03:11
Met Its Primary Endpoint in the ALEX Study
Chugai's picture
Chugai
04/09/2017 - 20:24
Phase III Study Shows Genentechs Alecensa Was Superior to Crizotinib in a Specific Type of Lung Cancer
Genentech's picture
Genentech
04/03/2017 - 00:06
Phase III ALUR study supports the use of Roches Alecensa for people with advanced ALK-positive lung cancer
Rocheusa's picture
Rocheusa
04/02/2017 - 10:19
Cancer Type and Mutation Identity Influenced Response to Targeted Therapy in a Basket Clinical Trial
American Association for Cancer Research's picture
American Associ...
04/02/2017 - 08:15
Combination HER2-targeted Therapy Effective in Heavily Pretreated HER2-positive Colorectal Cancer Patients
American Association for Cancer Research's picture
American Associ...
03/30/2017 - 11:56
Spectrum Pharmaceuticals Announces Initiation of a Phase 2 Trial of Poziotinib in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations
Spectrum's picture
Spectrum
03/29/2017 - 22:36
Phase III study shows Roches Alecensa was superior to crizotinib in a specific type of lung cancer
Rocheusa's picture
Rocheusa
03/28/2017 - 10:52
Astrazeneca to share its robust early science in oncology with the medical community at AACR 2017
AstraZeneca's picture
AstraZeneca
02/27/2017 - 03:45
Chugais ALK Inhibitor Alecensa
Chugai's picture
Chugai
02/21/2017 - 03:28
- Alecensa is Available Now in Japan, the United States and Europe -
Chugai's picture
Chugai
02/21/2017 - 01:16
Roche receives EU approval of Alecensa (alectinib) for people with previously treated ALK-positive non-small cell lung cancer
Rocheusa's picture
Rocheusa
02/09/2017 - 05:52
Afatinib to be evaluated in combination with PD-1 inhibitor pembrolizumab in new trial for patients with squamous cell carcinoma of the lung
Boehringer Ingelheim's picture
Boehringer-Ingelheim
01/18/2017 - 19:27
Daiichi Sankyo Initiates Phase 1/2 Study of Novel Antibody Drug Conjugate U3-1402 in Patients with HER3-Positive Metastatic or Unresectable Breast Cancer
Daiichi Sankyo's picture
Daiichi Sankyo
12/16/2016 - 14:37
CHMP recommends EU conditional approval of Roches Alecensa (alectinib) for people with previously treated ALK-positive NSCLC
Rocheusa's picture
Rocheusa
12/08/2016 - 07:47
Spectrum Pharmaceuticals Highlights Promising Preclinical Data Evaluating Poziotinib in Lung Cancer at the 17th IASLC World Conference on Lung Cancer
Spectrum's picture
Spectrum
12/01/2016 - 21:10
U.S. FDA Grants Fast Track Designation for HER2-Targeting Antibody Drug Conjugate DS-8201 for HER2-Positive Metastatic Breast Cancer
Daiichi Sankyo's picture
Daiichi Sankyo
11/30/2016 - 10:26
New Weizmann Institute of Science research provides hope for cancer patients
Weizmann Institute of Science's picture
WeizmannInstitute
11/29/2016 - 00:26
AstraZeneca takes latest scientific advances in oncology to major US And European congresses
AstraZeneca's picture
AstraZeneca
11/17/2016 - 07:20
Spectrum Pharmaceuticals Announces Poziotinib Data Presentation at the 17th IASLC World Conference on Lung Cancer in Vienna, Austria, December
Spectrum's picture
Spectrum
10/18/2016 - 12:33
New Drug Targets May Boost Protein Inhibitor, Survival for Lung Cancer Patients, Moffitt Cancer Center Study Shows
Moffitt's picture
Moffitt
10/04/2016 - 03:02
US FDA grants Breakthrough Therapy Designation for Roche's Alecensa (alectinib) for first-line treatment of people with ALK-positive NSCLC
Rocheusa's picture
Rocheusa
10/04/2016 - 00:14
Chugais Alecensa Receives Breakthrough Therapy Designation from FDA for First-Line Treatment of ALK Positive Non-Small Cell Lung Cancer
Chugai's picture
Chugai
10/02/2016 - 23:57
FDA Grants Breakthrough Therapy Designation for Genentechs Alecensa (Alectinib) for First-Line Treatment of People with ALK-Positive NSCLC
Genentech's picture
Genentech
09/15/2016 - 05:51
ArQule Announces Publication of Manuscript Highlighting Preclinical Activity of FGFR Inhibitor, ARQ 087, in Peer Reviewed Journal
ArQule's picture
ArQule
08/31/2016 - 06:43
XALKORI (Crizotinib) Receives Approval In European Union For The Treatment Of Patients With ROS1-Positive Advanced Non-Small Cell Lung Cancer
Pfizer's picture
Pfizer
07/13/2016 - 10:38
Boehringer Ingelheim and Lilly Announce Clinical Trial Collaboration in Metastatic Breast Cancer
Boehringer Ingelheim's picture
Boehringer-Ingelheim
06/30/2016 - 13:43
ArQule Presents Preliminary Clinical Data for ARQ 087 Demonstrating Evidence of Anticancer Activity in Intrahepatic Cholangiocarcinoma at the ESMO 18th World Congress on Gastrointestinal Cancer
ArQule's picture
ArQule
06/23/2016 - 22:27
The silencer: Study reveals how a cancer gene promotes tumor growth
Yale University's picture
YaleUniversity
06/23/2016 - 12:00
ArQule to Present Preliminary Phase 1/2 Data for FGFR Inhibitor, ARQ 087, in Intrahepatic Cholangiocarcinoma at the ESMO 18th World Congress on Gastrointestinal Cancer
ArQule's picture
ArQule
06/08/2016 - 21:54
Researchers prove lung cancer mutations can be detected in saliva
University of California Los Angeles's picture
UCLA
06/06/2016 - 04:07
Pfizer Presents Promising Data from Next Generation ALK/ROS1 Inhibitor in Advanced Non-Small Cell Lung Cancer
Pfizer's picture
Pfizer